A Phase 3 interventional study of Sevoflurane and Remifentanil in Anesthesia, Neurotoxicity and Child Development, sponsored by Murdoch Childrens Research Institute. Active, not recruiting at 21 sites in 4 countries. Open to participants aged Up to 2 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Murdoch Childrens Research Institute · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
There is considerable evidence that most general anaesthetics modulate brain development in animal studies. The impact is greater with longer durations of exposure and in younger animals. There is great controversy over whether or not these animal data are relevant to human clinical scenarios.
The changes seen in preclinical studies are greatest with GABA agonists and NMDA antagonists such as volatile anaesthetics (eg sevoflurane), propofol, midazolam, ketamine, and nitrous oxide. There is less evidence for an effect with opioid (such as remifentanil) or with alpha 2 agonists (such as dexmedetomidine).
Some, but not all, human cohort studies show an association between exposure to anaesthesia in infancy or early childhood and later changes in cognitive tests, school performance or risk of developing neurodevelopmental disorders. The evidence is weak due to possible confounding.
A recent well designed cohort study (the PANDA study) comparing young children that had hernia repair to their siblings found no evidence for a difference in a range of detailed neuropsychological tests. In that study most children were exposed to up to two hours of anaesthesia. The only trial (the GAS trial) has compared children having hernia repair under regional or general anesthesia and has found no evidence for a difference in neurodevelopment when tested at two years of age. The GAS and PANDA studies confirm the animal data that short exposure is unlikely to cause any neurodevelopmental impact.
The impact of longer exposures is still unknown. In humans the strongest evidence for an association between surgery and poor neurodevelopmental outcome is in infants having major surgery. However, this is also the group where confounding is most likely.
The aim of our study is to see if a new combination of anaesthetic drugs results in a better long-term developmental outcome than the current standard of care for children having anaesthesia expected to last 2 hours or longer.
Children will be randomised to receive either a low dose sevoflurane/remifentanil/dexmedetomidine or standard dose sevoflurane anaesthetic.
They will receive a neurodevelopmental assessment at 3 years of age to assess global cognitive function.
133 studies on the registry are indexed under Neurotoxicity Syndromes; 17 are open to participants now.
This study's enrollment of 450 is above the median of 92 across 86 interventional studies indexed under Neurotoxicity Syndromes.
Browse Neurotoxicity Syndromes studies →Murdoch Childrens Research Institute is the lead sponsor of 99 studies on the registry; 34 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dexmedetomidine: loading dose of 1mcg/kg over 10 minutes followed by an infusion of at 1 mcg/kg/hr. Remifentanil: loading dose 1 mcg/kg over 2 minutes followed by an infusion starting at 0.1 mcg/kg/min or greater. Sevoflurane: end tidal concentration of 0.6 -0.8% or less.
Drug: Sevoflurane · Drug: Remifentanil · Drug: Dexmedetomidine
End tidal concentration of 2.5-3.0% or greater.
Drug: Sevoflurane
Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.
Also known as: Sevorane
Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.
Also known as: Ultiva
Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.
Also known as: Precedex, Dexmedetomidine Ever Pharma
Full Scale IQ
Global cognitive function as assessed by the full scale IQ score of the Wechsler Preschool and Primary School Intelligence Scale.
Time frame: 3 years of age
incidence of intra-operative hypotension
Blood pressure measurements will be recorded during surgery
Time frame: 150 minutes- duration of surgery (baseline)
incidence of intra-operative bradycardia
Heart rate will be recorded during surgery
Time frame: 150 minutes- duration of surgery (baseline)
Post-operative pain
Pain scores will be recorded after surgery
Time frame: 60 minutes- after surgery
Time to recovery
Time of removal of airway, eye-opening and discharge from PACU will be recorded.
Time frame: 60 minutes- after surgery
Language outcomes
Clinical Evaluation of Language Fundamentals- Preschool, Version 2 (CELF-P2)
Time frame: 3 years of age
Attention/Executive Function/impulse control
A Developmental NEuroPSYchological Assessment- Second Edition (NEPSY-2): Statue Subtest
Time frame: 3 years of age
Memory
A Developmental NEuroPSYchological Assessment- Second Edition (NEPSY-2): Narrative memory
Time frame: 3 years of age
Adaptive behaviour
Adaptive Behavior Assessment System - Third Edition (ABAS-III)
Time frame: 3 years of age
Clinical Behavior
Child Behavior Checklist (CBCL)
Time frame: 3 years of age
Executive Function
Behavior Rating of Executive Function- Preschool (BRIEF-P)
Time frame: 3 years of age
Social Skills
Social Skills Improvement System (SSIS)
Time frame: 3 years of age
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The de-identified data set collected for this analysis of the TREX trial will be available six months after publication of the primary outcome. The study protocol, analysis plan and consent forms will also be available. The data may be obtained from the Murdoch Children's Research Institute by emailing andrew.davidson@rch.org.au.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: 6 months after publication of primary outcome
Access criteria: Prior to releasing any data the following are required: a data access agreement must be signed between relevant parties, the TREX Trial Steering Committee must see and approve the analysis plan describing how the data will be analysed, there must be an agreement around appropriate acknowledgement and any additional costs involved must be covered. Data will only be shared with a recognised research institution which has approved the proposed analysis plan.
Started Aug 2017 (actual). Primary completion is estimated for Dec 2026, 112 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Remifentanil · Dexmedetomidine
Murdoch Childrens Research Institute